GRANULES - Investment Analysis

Last Updated Time : 02 Aug 25, 12:58 am

📈 Investment Analysis: Granules India Ltd. (GRANULES)

Investment Rating: 3.9

🌟 Long-Term Investment Potential

Granules India operates in the pharmaceutical space and exhibits decent fundamentals with moderate valuation, healthy ROCE, and stable profitability. It’s not a “high-growth rocket,” but it’s a consistent performer suitable for conservative portfolios looking for quality over thrill.

✅ Strengths

ROCE: 15.1% & ROE: 13.9% — Suggests solid capital efficiency.

Low Debt-to-Equity (0.39) — Financially disciplined balance sheet.

EPS: ₹20.7 & PE of 24.8 — Reasonably priced against industry average PE of 34.

Price hovering near DMA levels — ₹490 near DMA50 (₹492), indicating consolidation zone.

Steady profit growth (PAT Qtr: ₹131 Cr.) — Gradual increase over previous quarter.

⚠️ Weaknesses

PEG Ratio: 5.01 — Very high, implying steep valuation relative to earnings growth.

Dividend Yield: 0.31% — Not attractive for income-focused investors.

FII holding reduced by 1.9% — Indicates waning institutional interest.

MACD: -5.44 — Bearish technical crossover.

52W High far from current levels (₹725 vs ₹490) — Sentiment recovery may take time.

🎯 Ideal Entry Price Zone

₹460–₹480

Technical support around ₹470, just above its 52-week low.

Favor accumulation if PEG normalizes to <2 and RSI stabilizes around 50.

Ideal for SIP-style staggered entry with a 1–2 year view.

⏳ Strategy for Existing Holders

📆 Holding Period Suggestion

18–24 Months

Long enough to watch product pipeline expansion, export traction, and margin improvement.

🚪 Exit Strategy

Exit if

Price hits ₹685–₹725 near 52W High zone without improvement in PEG.

PEG remains >4 and ROCE or ROE shows declining trend over 2 quarters.

RSI dips below 40 with price crossing below ₹440.

FII holding drops consistently for 3 quarters and volume dries up.

💡 Final Thought

Granules is like the reliable second starter in your pharma lineup — not aggressive, but dependable. While the PEG ratio raises red flags for fresh entries, the underlying business isn't broken. A close watch on growth catalysts and PEG normalization could unlock value over the next couple of years.

Want to compare this with Divi's Labs or Laurus Labs to build a pharma mini-portfolio? I can lay that out for you in a heartbeat.

Edit in a page